MRI with Hyperpolarized Pyruvate for Advanced Prostate Cancer
Trial Summary
What is the purpose of this trial?
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients. In the proposed study, the investigators aim is to extend the initial clinical results and further develop HP C-13 MRI as an imaging modality in advanced prostate cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on anti-coagulation medication and plan to undergo an optional tumor biopsy, you must be able to safely stop this treatment for the procedure.
What data supports the effectiveness of the treatment Hyperpolarized C13, Hyperpolarized 13C-Pyruvate, HP 13C Pyruvate, Hyperpolarized Carbon-13 Pyruvate for advanced prostate cancer?
Research shows that hyperpolarized 13C-pyruvate MRI can safely and effectively detect changes in tumor metabolism in prostate cancer, providing valuable information for diagnosis and treatment monitoring. This technique has demonstrated promising results in identifying cancer aggressiveness and early treatment response, making it a useful tool in managing prostate cancer.12345
Is MRI with Hyperpolarized Pyruvate safe for humans?
How is the treatment using MRI with Hyperpolarized Pyruvate different from other prostate cancer treatments?
This treatment is unique because it uses hyperpolarized pyruvate in MRI to provide real-time images of cancer metabolism, allowing doctors to see how prostate cancer cells process energy differently. This approach offers a noninvasive way to detect and monitor cancer by tracking metabolic changes, which is not possible with standard imaging techniques.12378
Research Team
Ivan de Kouchkovsky, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for men with advanced prostate cancer who can follow study procedures and have an ECOG status of 0 or 1, meaning they are fully active or restricted in physically strenuous activity but ambulatory. They must have a target lesion suitable for MRI imaging and no history of bleeding issues if undergoing biopsy. Men with certain metal implants, inability to consent, or contraindications to MRI cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants undergo baseline metabolic MR imaging with hyperpolarized C-13 pyruvate to assess metabolic flux in target lesions
Treatment Monitoring
Participants in Cohort B undergo repeat metabolic MRI at baseline and 12 weeks to monitor response to systemic therapies
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
Treatment Details
Interventions
- Hyperpolarized C13
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ivan de Kouchkovsky, MD
Lead Sponsor
Rahul Aggarwal
Lead Sponsor
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Collaborator
National Cancer Institute (NCI)
Collaborator